Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

53 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
nextMONARCH: Abemaciclib Monotherapy or Combined With Tamoxifen for Metastatic Breast Cancer.
Hamilton E, Cortes J, Ozyilkan O, Chen SC, Petrakova K, Manikhas A, Jerusalem G, Hegg R, Huober J, Chapman SC, Lu Y, Hardebeck MC, Bear MM, Johnston EL, Martin M. Hamilton E, et al. Among authors: manikhas a. Clin Breast Cancer. 2021 Jun;21(3):181-190.e2. doi: 10.1016/j.clbc.2020.09.011. Epub 2020 Sep 30. Clin Breast Cancer. 2021. PMID: 33148479 Clinical Trial.
nextMONARCH Phase 2 randomized clinical trial: overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with endocrine-refractory HR + , HER2- metastatic breast cancer.
Hamilton E, Cortes J, Ozyilkan O, Chen SC, Petrakova K, Manikhas A, Jerusalem G, Hegg R, Huober J, Zhang W, Chen Y, Martin M. Hamilton E, et al. Among authors: manikhas a. Breast Cancer Res Treat. 2022 Aug;195(1):55-64. doi: 10.1007/s10549-022-06662-9. Epub 2022 Jul 12. Breast Cancer Res Treat. 2022. PMID: 35829935 Free PMC article. Clinical Trial.
A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2- advanced breast cancer (BELLE-4).
Martín M, Chan A, Dirix L, O'Shaughnessy J, Hegg R, Manikhas A, Shtivelband M, Krivorotko P, Batista López N, Campone M, Ruiz Borrego M, Khan QJ, Beck JT, Ramos Vázquez M, Urban P, Goteti S, Di Tomaso E, Massacesi C, Delaloge S. Martín M, et al. Among authors: manikhas a. Ann Oncol. 2017 Feb 1;28(2):313-320. doi: 10.1093/annonc/mdw562. Ann Oncol. 2017. PMID: 27803006 Free article. Clinical Trial.
Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer.
Baselga J, Manikhas A, Cortés J, Llombart A, Roman L, Semiglazov VF, Byakhov M, Lokanatha D, Forenza S, Goldfarb RH, Matera J, Azarnia N, Hudis CA, Rozencweig M. Baselga J, et al. Among authors: manikhas a. Ann Oncol. 2014 Mar;25(3):592-598. doi: 10.1093/annonc/mdt543. Epub 2014 Jan 8. Ann Oncol. 2014. PMID: 24401928 Free PMC article. Clinical Trial.
A randomized phase II trial of doxorubicin plus pemetrexed followed by docetaxel versus doxorubicin plus cyclophosphamide followed by docetaxel as neoadjuvant treatment of early breast cancer.
Schneeweiss A, Marmé F, Ruiz A, Manikhas AG, Bottini A, Wolf M, Sinn HP, Mansouri K, Kennedy L, Bauknecht T. Schneeweiss A, et al. Among authors: manikhas ag. Ann Oncol. 2011 Mar;22(3):609-617. doi: 10.1093/annonc/mdq400. Epub 2010 Aug 23. Ann Oncol. 2011. PMID: 20732932 Free article. Clinical Trial.
Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study.
Semiglazov V, Eiermann W, Zambetti M, Manikhas A, Bozhok A, Lluch A, Tjulandin S, Sabadell MD, Caballero A, Valagussa P, Baselga J, Gianni L. Semiglazov V, et al. Among authors: manikhas a. Eur J Surg Oncol. 2011 Oct;37(10):856-63. doi: 10.1016/j.ejso.2011.07.003. Epub 2011 Aug 16. Eur J Surg Oncol. 2011. PMID: 21843921 Clinical Trial.
[HER2-positive breast cancer: standard and double targeted therapy].
Semiglazov VF, Bozhok AA, Semiglazova TIu, Vasil'ev AG, Manikhas AG, Semiglazov VV, Bessonov AA, Nikolaev KS. Semiglazov VF, et al. Among authors: manikhas ag. Vopr Onkol. 2013;59(3):341-6. Vopr Onkol. 2013. PMID: 23909035 Clinical Trial. Russian.
[BREAST-CONSERVING SURGERY AFTER NEOADJUVANT THERAPY FOR BREAST CANCER].
Semiglazov VF, Semiglazov VV, Petrenko OL, Komyakhov AV, Dashyan GA, Paltuev RM, Semiglazova TY, Manikhas AG, Bozhok AA, Lalak IA. Semiglazov VF, et al. Among authors: manikhas ag. Vopr Onkol. 2015;61(3):381-6. Vopr Onkol. 2015. PMID: 26242149 Clinical Trial. Russian.
Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer.
Baselga J, Manikhas A, Cortés J, Llombart A, Roman L, Semiglazov VF, Byakhov M, Lokanatha D, Forenza S, Goldfarb RH, Matera J, Azarnia N, Hudis CA, Rozencweig M. Baselga J, et al. Among authors: manikhas a. Ann Oncol. 2019 Jun 1;30(6):1017. doi: 10.1093/annonc/mdy529. Ann Oncol. 2019. PMID: 30624616 Free PMC article. No abstract available.
[Results of a prospective randomized investigation [Russia (St.Petersburg)/WHO] to evaluate the significance of self-examination for the early detection of breast cancer].
Semiglazov VF, Manikhas AG, Moiseenko VM, Protsenko SA, Kharikova RS, Seleznev IK, Popova RT, Migmanova NSh, Orlov AA, Barash NIu, Ivanova OA, Ivanov VG. Semiglazov VF, et al. Among authors: manikhas ag. Vopr Onkol. 2003;49(4):434-41. Vopr Onkol. 2003. PMID: 14569932 Clinical Trial. Russian.
53 results